{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:32:09Z","timestamp":1789824729072,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejpn.2020.12.002","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T03:21:36Z","timestamp":1607397696000},"page":"17-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3974-0394","authenticated-orcid":false,"given":"Bastien","family":"Estublier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Hoebeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Pichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Scavarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Desguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Auvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Chabrol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5333","key":"10.1016\/j.ejpn.2020.12.002_bib1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1126\/science.277.5333.1802","article-title":"Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis","volume":"277","author":"Sleat","year":"1997","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejpn.2020.12.002_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pediatrneurol.2013.08.008","article-title":"Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes","volume":"50","author":"Jadav","year":"2014","journal-title":"Pediatric Neurol."},{"key":"10.1016\/j.ejpn.2020.12.002_bib3","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/B978-0-444-59565-2.00038-1","article-title":"Neuronal ceroid lipofuscinoses","volume":"113","author":"Chabrol","year":"2013","journal-title":"Handb. Clin. Neurol."},{"issue":"11","key":"10.1016\/j.ejpn.2020.12.002_bib4","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.bbadis.2013.04.008","article-title":"NCL diseases \u2014 clinical perspectives","volume":"1832","author":"Schulz","year":"2013","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis.;nov"},{"issue":"8","key":"10.1016\/j.ejpn.2020.12.002_bib5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","article-title":"Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study","volume":"2","author":"Nickel","year":"2018","journal-title":"The Lancet Child & Adolescent Health"},{"key":"10.1016\/j.ejpn.2020.12.002_bib6","doi-asserted-by":"crossref","unstructured":"Dozi\u00e8res-Puyravel B, Nasser H, Elmaleh-Berg\u00e8s M, Lopez Hernandez E, Gelot A, Ilea A, et\u00a0al, Paediatric-onset neuronal ceroid lipofuscinosis: first symptoms and presentation at diagnosis. Developmental Medicine & Child Neurology [Internet]. 5 sept 2019 [cit\u00e9 8 nov 2019]; Disponible Sur: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/dmcn.14346.","DOI":"10.1111\/dmcn.14346"},{"issue":"6","key":"10.1016\/j.ejpn.2020.12.002_bib7","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1086\/302427","article-title":"Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder","volume":"64","author":"Sleat","year":"1999","journal-title":"Am. J. Hum. Genet."},{"issue":"1\u20132","key":"10.1016\/j.ejpn.2020.12.002_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ymgme.2016.07.011","article-title":"Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): expert recommendations for early detection and laboratory diagnosis","volume":"119","author":"Fietz","year":"2016","journal-title":"Mol. Genet. Metabol."},{"issue":"3","key":"10.1016\/j.ejpn.2020.12.002_bib9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ymgme.2011.06.018","article-title":"Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis","volume":"104","author":"Vuillemenot","year":"2011","journal-title":"Mol. Genet. Metabol."},{"issue":"1\u20132","key":"10.1016\/j.ejpn.2020.12.002_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2015.05.005","article-title":"Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis","volume":"116","author":"Lu","year":"2015","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejpn.2020.12.002_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2016.10.022","article-title":"Intracerebroventricular delivery as a safe, long-term route of drug administration","volume":"67","author":"Cohen-Pfeffer","year":"2017","journal-title":"Pediatr. Neurol."},{"issue":"20","key":"10.1016\/j.ejpn.2020.12.002_bib12","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejpn.2020.12.002_bib13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ajmg.10660","article-title":"Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients withCLN2 mutations","volume":"112","author":"Steinfeld","year":"2002","journal-title":"Am. J. Med. Genet."},{"issue":"6","key":"10.1016\/j.ejpn.2020.12.002_bib14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/01.wnl.0000267885.47092.40","article-title":"Neurological deterioration in late infantile neuronal ceroid lipofuscinosis","volume":"69","author":"Worgall","year":"2007","journal-title":"Neurol."},{"key":"10.1016\/j.ejpn.2020.12.002_bib15","article-title":"An adapted clinical measurement tool for the key symptoms of CLN2 disease","volume":"6","author":"Wyrwich","year":"2018","journal-title":"J.\u00a0Inborn Errors Metabol. Screen."},{"issue":"11","key":"10.1016\/j.ejpn.2020.12.002_bib16","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/humu.23860","article-title":"Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease","volume":"40","author":"Gardner","year":"2019","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejpn.2020.12.002_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.clim.2018.09.003","article-title":"Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: results from a Phase 1\/2 study","volume":"197","author":"Cherukuri","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejpn.2020.12.002_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eplepsyres.2018.05.005","article-title":"Late-onset childhood neuronal ceroid lipofuscinosis: early clinical and electroencephalographic markers","volume":"144","author":"Beltr\u00e1n","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejpn.2020.12.002_bib19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","article-title":"Management Strategies for CLN2 disease","volume":"69","author":"Williams","year":"2017","journal-title":"Pediatr. Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2020.12.002_bib20","article-title":"Impact of severe polyhandicap on parents' quality of life: a large French cross-sectional study","volume":"14","author":"Rousseau","year":"2019","journal-title":"Montazeri A, \u00e9diteur. Plos One."},{"key":"10.1016\/j.ejpn.2020.12.002_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ridd.2017.12.015","article-title":"Considering quality of life in end-of-life decisions for severely disabled children","volume":"73","author":"Zaal-Schuller","year":"2018","journal-title":"Res. Dev. Disabil."},{"issue":"4","key":"10.1016\/j.ejpn.2020.12.002_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40263-019-00620-8","article-title":"Current and emerging treatment Strategies for neuronal ceroid lipofuscinoses","volume":"33","author":"Kohlsch\u00fctter","year":"2019","journal-title":"CNS drugs."},{"issue":"1","key":"10.1016\/j.ejpn.2020.12.002_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(18)30368-5","article-title":"Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis","volume":"18","author":"Mole","year":"2019","journal-title":"Lancet Neurol."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379820302233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379820302233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:37:01Z","timestamp":1761071821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379820302233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":23,"alternative-id":["S1090379820302233"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2020.12.002","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2020.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}